Abstract
Oral 5-aminosalicylic acid (5-ASA) are well recognised to have the potential to cause drug-induced acute pancreatitis; however, there have only been infrequent case reports of rectal formulations causing acute pancreatitis. We describe a case of rectal Mesalazine (a 5-ASA) induced acute pancreatitis. The patient was commenced on rectal 5-ASA therapy 8weeks prior to presentation following a diagnosis of Montreal classification E1 Ulcerative Colitis on colonoscopy. After the diagnosis of acute pancreatitis was confirmed, 5-ASA was ceased and the patient made a clinical full recovery at 2month follow-up. Despite its reduced systemic absorption, rectal 5-ASA like oral formations must be considered as a potential trigger for acute pancreatitis in patients with inflammatory bowel disease.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have